

9 Literaturverzeichnis

1. Morson, B.C. Prevention of colorectal cancer. *J. R. Soc. Med.*, 72 (2): 83-5, 1979.
2. Muto, T., Bussey, H. J., and Morson, B.C. The evolution of cancer of the colon and rectum. *Cancer*, 36 (6): 2251-70, 1975.
3. Shimoda, T., Ikegami, M., Fujisaki, J., Matsui, T., Aizawa, S., and Ishikawa, E. Early colorectal carcinoma with special reference to its development de novo. *Cancer*, 64 (5): 1138-46, 1989.
4. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigenesis. *Cell*, 61 (5): 759-67, 1990. Review.
5. Bodmer, W. F., Bailey, C. J., Bodmer, J., Bussey, H. J., Ellis, A., Gorman, P., Lucibello, F.C., Murday, V. A., Rider, S. H., and Scambler, P. Localization of the gene for familial adenomatous polyposis on chromosome 5. *Nature*, 328 (6131): 614-6, 1987.
6. Nishisho, I., Nakamura, Y., Miyoshi, Y., Miki, Y., Ando, H., Horii, A., Koyama, K., Utsunomiya, J., Baba, S., and Hedge, P. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. *Science*, 253 (5020): 665-9, 1991.
7. Cho, K. R., Oliner, J. D., Simons, J. W., Hedrick, L., Fearon, E. R., Preisinger, A. C., Hedge, P., Silverman, G. A., and Vogelstein B. The DCC gene: structural analysis and mutations in colorectal carcinomas. *Genomics*, 19 (3): 525-31, 1994.
8. Powell, S. M., Zilz, N., Beazer-Barclay, Y., Bryan, T. M., Hamilton, S. R., Thibodeau, S. N., Vogelstein, B., and Kinzler, K. W. APC mutations occur early during colorectal tumorigenesis. *Nature*, 359 (6392): 235-7, 1992.
9. Sasaki, M., Okamoto, M., Sato, C., Sugio, K., Soejima, J., Iwama, T., Ikeuch, T., Tonomura, A., Miyaki, M., and Sasazuki, T. Loss of constitutional heterozygosity in

- colorectal tumors from patients with familial polyposis coli and those with nonpolyposis colorectal carcinoma. *Cancer Res.*, 49 (16): 4402-6, 1989.
10. Mann, B., Gelos, M., Siedow, A., Hanski, M. L., Gratchev, A., Ilyas, M., Bodmer, W. F., Moyer, M. P., Riecken, E. O., Buhr, H. J., and Hanski, C. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. *Proc. Natl. Acad. Sci.*, 96 (4):1603-8, 1999.
 11. Goelz, S. E., Vogelstein, B., Hamilton, S. R., and Feinberg, A. P. Hypomethylation of DNA from benign and malignant human colon neoplasms. *Science*, 228 (4696): 187-90, 1985.
 12. Silverman, A. L., Park, J. G., Hamilton, S. R., Gazdar, A. F., Luk, G. D., and Baylin, S. B. Abnormal methylation of the calcitonin gene in human colonic neoplasms. *Cancer Res.*, 49 (13): 3468-73, 1989.
 13. Weinberg, R. A. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. *Cancer Res.*, 49 (14): 3713-21, 1989. Review.
 14. Vogelstein, B., Fearon, E. R., Kern, S. E., Hamilton, S. R., Preisinger, A. C., Nakamura, Y., and White, R. Allelotype of colorectal carcinomas. *Science*, 244 (4901): 207-11, 1989.
 15. Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A. M., and Bos, J. L. Genetic alterations during colorectal-tumor development. *N. Engl. J. Med.*, 319 (9): 525-32, 1988.
 16. Bos, J. L., Fearon, E. R., Hamilton, S. R., Verlaan-de Vries, M., van Boom, J. H., van der Eb, A. J., and Vogelstein, B. Prevalence of ras gene mutations in human colorectal cancers. *Nature*, 327 (6120): 293-7, 1987.

17. Bos, J. L. p21ras: an oncoprotein functioning in growth factor-induced signal transduction. *Eur. J. Cancer*, 31A (7-8): 1051-4, 1995. Review.
18. Itoh, F., Hinoda, Y., and Ohe, M. Decreased expression in DCC mRNA in human colorectal cancers. *Int. J. Cancer*, 53: 260-263, 1993.
19. Baker, S. J., Fearon, E. R., Nigro, J.M., Hamilton, S.R., Preisinger, A. C., Jessup, J. M., van Tuinen, P., Ledbetter, D. H., Barker, D. F., and Nakamura, Y. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. *Science*, 244 (4901): 217-21, 1989.
20. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. *Cancer Res.*, 54 (18): 4855-78, 1994. Review.
21. Fishel, R., Lescoe, M. K., Rao, M. R., Copeland, N. G., Jenkins, N. A., Garber, J., Kane, M., and Kolodner, R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. *Cell*, 75 (5): 1027-38, 1993.
22. Fishel, R., and Kolodner, R. D. Identification of mismatch repair genes and their role in the development of cancer. *Curr. Opin. Genet. Dev.*, 5 (3): 382-95, 1995. Review.
23. Peinado, M. A., Malkhosyan, S., Velazquez, A., and Perucho, M. Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction. *Proc. Natl. Acad. Sci. USA*, 89 (21): 10065-9, 1992.
24. Ionov, Y., Peinado, M. A., Malkhosyan, S., Shibata, D., and Perucho, M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. *Nature*, 363 (6429): 558-61, 1993.

25. Boland, C. R., Sato, J., Saito, K., Carethers, J. M., Marra, G., Laghi, L., and Chauhan, D. P. Genetic instability and chromosomal aberrations in colorectal cancer: a review of the current models. *Cancer Detect. Prev.*, 22 (5): 377-82, 1998. Review.
26. Aaltonen, L. A., Peltomaki, P., Leach, F. S., Sistonen, P., Pylkkanen, L., Mecklin, J. P., Jarvinen, H., Powell, S. M., Jen, J., and Hamilton, S. R. Clues to the pathogenesis of familial colorectal cancer. *Science*, 260 (5109): 812-6, 1993.
27. Thibodeau, S. N., Bren, G., and Schaid, D. Microsatellite instability in cancer of the proximal colon. *Science*, 260 (5109): 816-9, 1993.
28. Modrich, P. Mechanisms and biological effects of mismatch repair. *Annu. Rev. Genet.*, 25: 229-53, 1991. Review.
29. Karran, P. Appropriate partners make good matches. *Science*, 268 (5219): 1857-8, 1995. Review.
30. Liu, B., Parsons, R., Papadopoulos, N., Nicolaides, N. C., Lynch, H. T., Watson, P., Jass, J. R., Dunlop, M., Wyllie, A., Peltomaki, P., de la Chapelle, A., Hamilton, S. R., Vogelstein, B., and Kinzler, K. W. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. *Nat. Med.* 2 (2): 169-74, 1996.
31. Cunningham, J. M., Christensen, E. R., Tester, D. J., Kim, C. Y., Roche, P. C., Burgart, L. J., and Thibodeau, S. N. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. *Cancer Res.*, 58 (15): 3455-60, 1998.
32. Knudson, A. G. Hereditary cancer: two hits revisited. *J. Cancer Res. Clin. Oncol.*, 122 (3): 135-40, 1996. Review.
33. Beroud, C., and Soussi, T. APC gene: database of germline and somatic mutations in human tumors and cell lines. *Nucleic Acids Res.*, 24 (1): 121-4, 1996.

34. Kinzler, K. W., and Vogelstein, B. Lessons from hereditary colorectal cancer. *Cell*, 87 (2): 159-70, 1996. Review.
35. Lynch, H. T., Smyrk, T. C., Watson, P., Lanspa, S. J., Lynch, J. F., Lynch, P. M., Cavalieri, R. J., and Boland, C. R. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. *Gastroenterology*, 104 (5): 1535-49, 1993. Review.
36. Kolodner, R. D., Hall, N. R., Lipford, J., Kane, M. F., Morrison, P. T., Finan, P. J., Burn, J., Chapman, P., Earabino, C., and Merchant, E. Structure of the human MLH1 locus and analysis of a large hereditary nonpolyposis colorectal carcinoma kindred for mlh1 mutations. *Cancer Res.*, 55 (2): 242-8, 1995.
37. Rhyu, M.S. Molecular mechanisms underlying hereditary nonpolyposis colorectal carcinoma. *J. Natl. Cancer Inst.*, 88 (5): 240-51, 1996. Review.
38. Hanski, C., Hofmeier, M., Schmitt-Gräff, A., Riede, E., Hanksi, M. L., Borchard, F., Sieber, E., Niedobitek, F., Foss, H.-D., Stein, H., and Riecken, E. O. Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary. *J. Pathology*, 182: 385-391, 1997.
39. Hamelin, R., Laurent-Puig, P., Olschwang, S., Jego, N., Asselain, B., Remvikos, Y., Girodet, J., Salmon, R. J., and Thomas, G. Association of p53 mutations with short survival in colorectal cancer. *Gastroenterology*, 106 (1): 42-8, 1994.
40. Costa, A., Marasca, R., Valentini, B., Savarino, M., Faranda, A., Silvestrini, R., and Torelli, G. p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. *J. Pathol.*, 176 (1): 45-53, 1995.
41. Laurent-Puig, P., Olschwang, S., Delattre, O., Validire, P., Melot, T., Mosseri, V., Salmon, R. J., and Thomas, G. Association of Ki-ras mutation with differentiation and tumor-formation pathways in colorectal carcinoma. *Int. J. Cancer*, 49 (2): 220-3, 1991.

42. Hedrick, L., Cho, K. R., Fearon, E. R., Wu, T. C., Kinzler, K. W., and Vogelstein, B. The DCC gene product in cellular differentiation and colorectal tumorigenesis. *Genes Dev.*, 8 (10): 1174-83, 1994.
43. Kim, H., Jen, J., Vogelstein, B., and Hamilton, S. R. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. *Am. J. Pathol.*, 145 (1): 148-56, 1994.
44. Backert, S., Gelos, M., Kobalz, U., Hanski, M. L., Bohm, C., Mann, B., Lovin, N., Gratchev, A., Mansmann, U., Moyer, M. P., Riecken, E. O., and Hanski C. Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array. *Int. J. Cancer*, 82 (6): 868-74, 1999.
45. Heidelberger, C., Chaudhuri N. K., and Danneberg, P. Fluorinated pyrimidines, a new class of tumorinhibitory compounds. *Nature*, 179: 663-666, 1957.
46. Parker, W. B., and Cheng, Y.C. Metabolism and mechanism of action of 5-fluorouracil. *Pharmacol. Ther.*, 48(3): 381-95, 1990. Review.
47. Major, P. P., Egan, E., Herrick, D., and Kufe D. W. 5-Fluorouracil incorporation in DNA of human breast carcinoma cells. *Cancer Res.*, 42 (8): 3005-9, 1982.
48. Peters, G. J., van der Wilt, C.L., van Triest, B., Codacci-Pisanelli, G., Johnston, P. G., van Groeningen, C. J., and Pinedo, H. M. Thymidylate synthase and drug resistance. *Eur. J. Cancer*, 31A (7-8): 1299-305, 1995. Review.
49. Goldwasser, F., Shimizu, T., Jackman, J., Hoki, Y., O'Connor, P. M., Kohn, K. W., and Pommier, Y. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. *Cancer Res.*, 56 (19): 4430-7, 1996.

50. Rothenberg, M.L., and Blanke, C.D. Topoisomerase I inhibitors in the treatment of colorectal cancer. *Seminars in Oncology*, 26 (6): 632-639, 1999.
51. Vanhoefer, U., Harstrick, A., Achterrath, W., Cao, S., Seeber, S., and Rustum, Y. M. Irinotecan in the treatment of colorectal cancer: clinical overview. *J. Clin. Oncol.*, 19: 1501-1518, 2001.
52. Whitacre, C. M., Zborowska, E., Willson, J. K., and Berger, N. A. Detecton of poly(ADP-ribose) Polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness. *Clin. Cancer Res.*, 5: 665-672, 1999.
53. Lansiaux, A., Bras-Goncalves, R. A., Rosty, C., Laurent-Puig, P., Poupon, M. F., and Bailly, C. Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status : relation with their sensitivity to CPT-11. *Anticancer Res.*, 21: 471-476, 2001.
54. Pommier, Y., Kohlhagen, G., Kohn, K. W., Leteurtre, F., Wani, M. C., and Wall, M. E. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. *Proc. Natl. Acad. Sci. USA*, 92 (19): 8861-5, 1995.
55. Guichard, S., Terret, C., Hennebelle, I., Lochon, I., Chevreau, P., Fretigny, E., Selves, J., Chatelut, E., Bugat, R., and Canal, P. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. *Br. J. Cancer*, 80 (3-4): 364-70, 1999.
56. Jansen, W. J., Zwart, B., Hulscher, S.T., Giaccone, G., Pinedo, H. M., and Boven, E. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. *Int. J. Cancer*, 70 (3): 335-40, 1997.
57. Nieves-Neira, W., and Pommier, Y. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI

- Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. *Int. J. Cancer.*, 82 (3): 396-404, 1999.
58. Omura, S., Tanaka, H., Oiwa, R., Awaya, J., Masuma, R., and Tanaka, K. New antitumor antibiotics, OS-4742 A1, A2, B1 and B2 produced by a strain of *Streptomyces*. *J. Antibiot. (Tokyo)*, 30 (11): 908-16, 1977.
59. Takahashi, I., Kobayashi, E., Asano, K., Yoshida, M., and Nakano, H. UCN-01, a selective inhibitor of protein kinase C from *Streptomyces*. *J. Antibiot. (Tokyo)*, 40 (12): 1782-4, 1987.
60. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. *Cancer Chemother. Pharmacol.*, 33(4): 273-80, 1994.
61. Kawakami, K., Futami, H., Takahara, J., and Yamaguchi, K. UCN-01, 7-hydroxystaurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. *Biochem. Biophys. Res. Commun.*, 219 (3): 778-83, 1996.
62. Akiyama, T., Yoshida, T., Tsujita, T., Shimizu, M., Mizukami, T., Okabe, M., and Akinaga, S. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. *Cancer Res.*, 57 (8): 1495-501, 1997.
63. Akiyama, T., Sugiyama, K., Shimizu, M., Tamaoki, T., and Akinaga, S. G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-Hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation. *Jpn. J. Cancer Res.*, 90: 1364-1372, 1999.

64. Usuda, J., Saijo, N., Fukuoka, K., Fukumoto, H., Kuh, H. J., Nakamura, T., Koh, Y., Suzuki, T., Koizumi, F., Tamura, T., Kato, H., and Nishio, K. Molecular determinants of UCN-01-induced growth inhibition in human lung cancer cells. *Int. J. Cancer*, 85 (2): 275-80, 2000.
65. Fan, G., and Steer, C. J. The retinoblastoma gene product is a negative modulator of the apoptotic pathway. *Adv. Enzyme Regul.*, 36: 283-303, 1996.
66. DeGregori, J., Leone, G., Ohtani, K., Miron, A., and Nevins, J. R. E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. *Genes Dev.*, 9 (23): 2873-87, 1995.
67. Akinaga, S., Sugiyama, K., and Akiyama, T. UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: a new generation of anti-cancer agents for the new century? *Cancer Drug Design*, 15: 43-52, 2000.
68. Graves, P. R., Yu, L., Schwarz, J.K., Gales, J., Sausville, E. A., O'Connor, P. M., and Piwnicka-Worms, H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. *J. Biol. Chem.*, 275 (8): 5600-5, 2000.
69. Busby, E. C., Leistritz, D. F., Abraham, R. T., Karnitz, L. M., and Sarkaria, J. N., The radiosensitizing agent 7-Hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. *Cancer Research*, 60: 2108-2112, 2000.
70. Sherr, C. J. G1 phase progression: cycling on cue. *Cell*, 79 (4): 551-5, 1994. Review.
71. Morgan, D. O. Principles of CDK regulation. *Nature*, 374 (6518): 131-4, 1995. Review.
72. Hamelin, R., Laurent-Puig, P., Olschwang, S., Jego, N., Asselain, B., Remvikos, Y., Girodet, J., Salmon, R. J., and Thomas G. Association of p53 mutations with short survival in colorectal cancer. *Gastroenterology*, 106 (1): 42-8, 1994.

73. Goh, H. S., Yao, J., and Smith, D. R. p53 point mutation and survival in colorectal cancer patients. *Cancer Res.*, 55 (22): 5217-21, 1995.
74. Johnson, M., Dimitrov, D., Vojta, P. J., Barrett, J. C., Noda, A., Pereira-Smith, O. M., and Smith, J. R. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. *Mol. Carcinog.*, 11 (2): 59-64, 1994.
75. Loignon, M., Fetni, R., Gordon, A. J., and Drobetsky, E. A. A p53-independent pathway for induction of p21waf1cip1 and concomitant G1 arrest in UV-irradiated human skin fibroblasts. *Cancer Res.*, 57 (16): 3390-4, 1997.
76. Haapajarvi, T., Kivinen, L., Heiskanen, A., des Bordes, C., Datto, M. B., Wang, X. F., and Laiho, M. UV radiation is a transcriptional inducer of p21(Cip1/Waf1) cyclin-kinase inhibitor in a p53-independent manner. *Exp. Cell Res.*, 248 (1): 272-9, 1999.
77. Kerr, J. F. R., Wyllie, A. H., and Currie, A. R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br. J. Cancer* 26 (4): 239-57, 1972. Review.
78. Kroemer, G., Zamzami, M., and Susin, S. A. Mitochondrial control of apoptosis. *Immunol. Today* 18: 44-51, 1997.
79. Sulston, J. R., and Horvitz, H. R. Post-embryonic cell lineages of the nematode, *Caenorhabditis elegans*. *Dev. Biol.* 56 (1): 110-56, 1977.
80. Hengartner, M. O., and Horvitz, H. R. Programmed cell death in *Caenorhabditis elegans*. *Curr. Opin. Genet. Dev.* 4: 581-586, 1994.
81. Golstein, P. Controlling cell death. *Science* 275:1081-2 1997.
82. Nicholson, D. W., and Thornberry, N. A. Caspases: Killer proteases. *TIBS* 22: 299-306, 1997.

83. Chang, B.-D., Broude, E., Dokmanovic, M., Zhu, H., Ruth, A., Xuan, Y., Kandel, E., Lausch, E., Christov, K., and Roninson, I. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. *Cancer Research*, 59:3761-3767, 1999.
84. Roninson If not apoptosis - then what? Treatment-induced senescence and mitotic catastrophe in tumour cells. *Drug Resistance Updates*, 2001.
85. Te Poele, R. H., Okorokov, A. L., Jardine, L., Cummings, J., and Joel, S. P. DNA damage is able to induce senescence in tumor cells *in vitro* and *in vivo*. *Cancer Research* 62: 1876-1883, 2002.
86. Gayet, J., Zhou, X. P., Duval, A., Rolland, S., Hoang, J. M., Cottu, P., and Hamelin, R. Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. *Oncogene*, 20 (36): 5025-32, 2001.
87. Heinen, C. D., Richardson, D., White, R., and Groden, J. Microsatellite instability in colorectal adenocarcinoma cell lines that have full-length adenomatous polyposis coli protein. *Cancer Res.*, 55 (21): 4797-9, 1995.
88. Shibata, D., Peinado, M. A., Ionov, Y., Malkhosyan, S., and Perucho, M. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. *Nat. Genet.*, 6 (3): 273-81, 1994.
89. Carethers, J. M., and Pham, T. T. Mutations of transforming growth factor beta 1 type II receptor, BAX, and insulin-like growth factor II receptor genes in microsatellite unstable cell lines. *In Vivo*, 14 (1): 13-20, 2000.
90. Lengauer, C., Kinzler, K. W., Vogelstein, B. Genetic instability in colorectal cancers. *Nature*, 386 (6625): 623-7, 1997.

91. Casares, S., Ionov, Y., Ge, H. Y., Stanbridge, E., and Perucho, M. The microsatellite mutator phenotype of colon cancer cells is often recessive. *Oncogene*, 11 (11): 2303-10, 1995.
92. Umar, A., and Kunkel T. A. DNA-replication fidelity, mismatch repair and genome instability in cancer cells. *Eur. J. Biochem.*, 238 (2): 297-307, 1996. Review.
93. Drummond, J. T., Li, G. M., Longley, M.J., and Modrich, P. Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. *Science*, 268 (5219): 1909-12, 1995.
94. Cahill, D. P., Lengauer, C., Yu, J., Riggins, G. J., Willson, J. K., Markowitz, S. D., Kinzler, K. W., and Vogelstein, B. Mutations of mitotic checkpoint genes in human cancers. *Nature*, 392 (6673): 300-3, 1998.
95. Jacob, S., Aguado, M., Fallik, D., and Praz, F. The role of the DNA mismatch repair system in the cytotoxicity of the Topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. *Cancer Res.*, 61: 6555-6562, 2001.
96. Kagawa, S., Fujiwara, T., Hizuta, A., Yasuda, T., Zhang, W. W., Roth, J. A., and Tanaka, N. p53 expression overcomes p21 WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells. *Oncogene*, 15(16): 1903-9, 1997.
97. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J. Jr., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. *Cancer Res.*, 57 (19): 4285-300, 1997.
98. Branch, P., Hampson, R., and Karran P. DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. *Cancer Res.*, 55 (11): 2304-9, 1995.

99. Nita, M. E., Nagawa, H., Tominaga, O., Tsuno, N., Fujii, S., Sasaki, S., Fu, C.-G., Takenoue, T., Tsuruo, T., and Muto, T. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. *British Journal of Cancer*, 78 (8): 986-992, 1998.
100. Moyer, M. P., Manzano, L. A., Merriman, R. L., Stauffer, J. S., and Tanzer, L. R. NCM460, a normal human colon mucosal epithelial cell line. *In Vitro Cell Dev. Biol. Anim.*, 32 (6): 315-7, 1996.
101. Boyer, J. C., Umar, A., Risinger, J. I., Lipford, J. R., Kane, M., Yin, S., Barret, J. C., Kolodner, R. D., and Kunkel, T. A. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. *Cancer Res.*, 55: 6063-6070, 1995.
102. Koi, M., Umar, A., Chauhan, D. P., Cherian, S. P., Carethers, J. M., Kunkel, T. A., and Boland, C. R. Human chromosome 3 corrects mismatch repair deficiency and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. *Cancer Research*, 54 (16): 4308-12, 1994.
103. Violette, S., Poulain, L., Dussaulx, E., Pepin, D., Faussat, A.-M., Chambaz, J., Lacorte, J.-M., Staedel, C., and Lesuffleur, T., Resistance of colon cancer cells to long-term 5-Fluorouracil exposure is correlated to the relative level of bcl-2 and bcl-x_L in addition to bax and p53 status. *Int. J. Cancer*, 98: 498-504, 2002.
104. Davis, T. W., Wilson-Van Patten, C., Meyers, M., Kunugi, K. A., Cuthill, S., Reznikoff, C., Garces, C., Boland, C. R., Kinsella, T. J., Fishel, R., and Boothman, D. A. Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation. *Cancer Res.*, 58 (4): 767-78, 1998.
105. Verstijnen, C. P., Arends, J. W., Moerkerk, P. T., Geraedts, J. P., Sekikawa, K., Uitendaal, M. P., and Bosman, F. T. The establishment and characterization of two new

- cell lines derived from a single human colonic adenocarcinoma. *Virchows Arch. B. Cell. Pathol. Incl. Mol. Pathol.* 53 (4): 191-7, 1987.
106. Smulson, M. E., Simbulan-Rosenthal, C. M., Boulares, A. H., Yakovlev, A., Stoica, B., Iyer, S., Luo, R., Haddad, B., Wang, Z. Q., Pang, T., Jung, M., Dritschilo, A., and Rosenthal, D. S. Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability and functions of p53 and E2F-1. *Adv. Enzyme Regul.*, 40: 183-215, 2000.
107. Sugiyama, K., Shimizu, M., Akiyama, T., Tamaoki, T., Yamaguchi, K., Takahashi, R., Eastman, A., and Akinaga, S. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation. *Int. J. Cancer*, 85 (5): 703-9, 2000.
108. Monks, A., Harris, E. D., Vaigro-Wolff, A., Curtis D. H., Connelly, J. W., and Sausville, E. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines. *Invest. New Drugs*, 18: 95-107, 2000.
109. Jones, C. B., Clements, M. K., Redkar, A., and Daoud, S. S. UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cells. *Int. J. Oncol.*, 17 (5): 1043-51, 2000.
110. Luo, Y., Rockow-Magnone, S. K., Joseph, M. K., Bradner, J., Butler, C. C., Tahir, S. K., Han, E. K., Ng, S. C., Severin, J. M., Gubbins, E. J., Reilly, R. M., Rueter, A., Simmer, R. L., Holzman, T. F., and Giranda, V. L. Abrogation of G2 checkpoint specifically sensitizes p53 defective cells to cancer chemotherapeutic agents. *Anticancer Res.*, 21(1A): 23-8, 2001.
111. Byrd, J. C., Shinn, C., Willis, C. R., Flinn, I. W., Lehman, T., Sausville, E., Lucas, D., and Grever, M. R. UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism. *Exp. Hematol.*, 29 (6): 703-8, 2001.

112. Hirose, Y., Berger, M. S., and Pieper, R. O. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. *Cancer Res.*, 61(15): 5843-9, 2001.
113. Sheikh, M. S., Chen, Y. Q., Smith, M. L., and Fornace, A. J. Jr. Role of p21Waf1/Cip1/Sdi1 in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells. *Oncogene*, 14 (15): 1875-82, 1997.
114. Yang, B., Eshleman, J. R., Berger, N. A., and Markowitz, S. D. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. *Clin. Cancer Res.*, 2 (10): 1649-57, 1996.
115. Vidair, C. A., Chen, C. H., Ling, C. C., and Dewey, W. C. Apoptosis induced by X-irradiation of rec-myc cells is postmitotic and not predicted by the time after irradiation or behavior of sister cells. *Cancer Res.*, 56 (18): 4116-8, 1996.
116. Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., and Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. *J. Clin. Invest.*, 104 (3): 263-9, 1999.
117. Pritchard, D. M., Watson, A. J., Potten, C. S., Jackman, A. L., and Hickman, J. A. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. *Proc. Natl. Acad. Sci. USA*, 94 (5): 1795-9, 1997.
118. Zheng, M., Wang, H., Zhang, H., Ou, Q., Shen, B., Li, N., and Yu B. The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells. *J. Cancer Res. Clin. Oncol.*, 125(6):357-60, 1999.
119. Osaki, T., Kimura, T., Tatemoto, Y., Dapeng, L., Yoneda, K., and Yamamoto, T. Diffuse mode of tumor cell invasion and expression of mutant p53 protein but not of

- p21 protein are correlated with treatment failure in oral carcinomas and their metastatic foci. *Oncology*, 59 (1): 36-43, 2000.
120. Bras-Goncalves, R. A., Rosty, C., Laurent-Puig, P., Soulie, P., Dutrillaux, B., and Poupon, M. F. Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. *Br. J. Cancer*, 82 (4): 913-23, 2000.
121. Osaki, S., Nakanishi, Y., Takayama, K., Pei, X. H., Ueno, H., and Hara, N. Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells. *Cancer Gene Ther.*, 7 (2): 300-7, 2000.
122. McDonald, A. C., and Brown, R. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. *Br. J. Cancer*, 78 (6): 745-51, 1998.
123. Xie, X., Sasai, K., Shibuya, K., Tachiiri, S., Nihei, K., Ohnishi, T., and Hiraoka, M. P53 status plays no role in radiosensitizing effects of SN-38, a camptothecin derivative. *Cancer Chemother. Pharmacol.*, 45 (5): 362-8, 2000.
124. Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., and Vogelstein, B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. *Science*, 282: 1497-1501, 1998.
125. Hirose, Y., Berger, M. S., and Pieper, R. O. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. *Cancer Res.*, 61: 1957-1963, 2001.
126. Meyers, M., Wagner, M. W., Hwang, H. S., Kinsella, T. J., and Boothman, D. A. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. *Cancer Res.*, 61: 5193-5201, 2001.
127. Husain, A., Yan, X. J., Rosales, N., Aghajanian, C., Schwartz, G. K., and Spriggs, D. R. UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-

- diamminedichloroplatinum(II)independent of p53 status. *Clin. Cancer Res.*, 3 (11): 2089-97, 1997.
128. Wang, S. H., Phelps, E., Utsugi, S., and Baker, J. R. Susceptibility of thyroid cancer cells to 7-hydroxystaurosporine-induced apoptosis correlates with Bcl-2 protein level. *Thyroid*, 11 (8): 725-31, 2001.
129. Shao, R. G., Cao, C. X., Shimizu, T., O'Connor, P. M., Kohn, K. W., and Pommier, Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. *Cancer Res.*, 57 (18): 4029-35, 1997.
130. Carethers, J. M., Chauhan, D. P., Fink, D., Nebel, S., Bresalier, R. S., Howell, S. B., and Boland, C. R. Mismatch repair proficiency and in vitro response to 5-fluorouracil. *Gastroenterology*, 117 (1): 123-31, 1999.
131. Friedman, H. S., Johnson, S. P., Dong, Q., Schold, S. C., Rasheed, B. K., Bigner, S. H., Ali-Osman, F., Dolan, E., Colvin, O. M., Houghton, P., Germain, G., Drummond, J. T., Keir, S., Marcelli, S., Bigner, D. D., and Modrich, P. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. *Cancer Res.*, 57 (14): 2933-6, 1997.
132. Fallik, D., Sabourin, J. C., Borrini, F., Jacob, S., Boige, V., Praz, F., and Ducreux, M. Response of metastatic colorectal cancers to treatment with CPT-11 (irinotecan): implications of the mismatched base repair system. *Gastroenterol. Clin. Biol.*, 24: 917-922, 2000.
133. Hemminki, A., Mecklin, J.-P., Järvinen, H., Aaltonen, L. A., and Joensuu, H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. *Gastroenterology*, 119: 921-928, 2000.

134. Elsaleh, H., Joseph, D., Grieu, F., Zeps, N., Spry, N., and Iacopetta, B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. *The Lancet*, 355: 1745-50, 2000.
135. Gryfe, R., Kim, H., Hsieh, E. T., Aronson, M. D., Holowaty, E. J., Bull, S. B., Redston, M., and Gallinger, S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. *N. Engl. J. Med.*, 342 (2): 69-77, 2000.
136. Elsaleh, H., Powell, B., and Soontrapornchai, P. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes's C colon carcinoma. *Oncology*,: 58: 52-9, 2000.
137. Hawn, M. T., Umar, A., Carethers, J. M., Marra, G., Kunkel, T. A., Boland, C. R., and Koi, M. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. *Cancer Res.*, 55: 3721-3725, 1995.
138. Magrini, R., Bhonde, M., Hanski, M. L., Notter, M., Scherübl, H., Boland, R., Zeitz, M., and Hanski, C. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. *Int. J. Cancer*, 101 (1): 23-31, 2002.
139. Chen, X., Lowe, M., and Keyomarsi, K. UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. *Oncogene*, 18: 5691-5702, 1999.
140. Bunch R. T., and Eastman, A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. *Clin. Cancer Res.*, 2 (5): 791-7, 1996.
141. Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., and O'Connor, P. M. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. *J. Natl. Cancer Inst.*, 88 (14): 956-65, 1996.

142. Lee, S., Brown, M., and Eastman, A. Comparison of the efficacy of 7-Hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines. *Biochem. Pharmacology*, 58: 1713-21, 1999.
143. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. *Cancer Chemother. Pharmacol.*, 32 (3): 183-9, 1993.
144. Hsueh, C., Kelsen D., and Schwatz, G. K. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-Fluorouracil-induced apoptosis in a sequence-dependent manner. *Clin. Cancer Res.*, 4: 2201-06, 1998.
145. Yu, Q., La Rose, J., Zhang, H., Takemura, H., Kohn, K., and Pommier, Y. UCN-01 inhibits p53 up-regulation and abrogates γ -radiation-induced G₂-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. *Cancer Research*, 62: 5743-5748, 2002.
146. Fuse, E., Tanii, H., Kurata, N., Kobayashi, H., Shimada, Y., Tamura, T., Sasaki, Y., Tanigawara, Y., Lush, R. D., Headlee, D., Figg, W. D., Arbuck, S. G., Senderowicz, A. M., Sausville, E. A., Akinaga, S., Kuwabara, T., and Kobayashi, S. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α 1-acid glycoprotein. *Cancer Research*, 58: 3248-53, 1998.